Response to ketoconazole after failure of docetaxel in patients with advanced androgen-independent prostate cancer (AIPC)

Authors :: S. M. GressettUssery
Sachin R Shah
Gary W. Jean
Jonathan E. Dowell
Sidney V Keisner
Source :: Journal of Clinical Oncology. 28:e15052-e15052
Publication Year :: 2010
Publisher :: American Society of Clinical Oncology (ASCO), 2010.
Abstract: e15052 Background: In AIPC, the combination of docetaxel and prednisone has been shown to increase overall survival and progression free survival. Ketoconazole is considered in patients with AIPC t...

Subjects :: Oncology
Cancer Research
medicine.medical_specialty
business.industry
Docetaxel
Androgen independent prostate cancer
Prednisone
Internal medicine
medicine
Overall survival
Ketoconazole
In patient
Progression-free survival
business
medicine.drug

Full Text Access

Tools